3160-38-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-METHYLPHENYL)-3-BUTEN-2-ONE 97 is used as a key intermediate in the synthesis of pharmaceutical compounds. Its involvement in the Reformatsky reaction allows for the creation of β-hydroxy esters, which are essential building blocks for various drug molecules. This application is crucial for the development of new medications and the improvement of existing ones.
Used in Chemical Industry:
In the chemical industry, 4-(4-METHYLPHENYL)-3-BUTEN-2-ONE 97 is utilized as a reactant in the Reformatsky reaction to produce β-hydroxy esters. These esters can be further transformed into other valuable chemicals, contributing to the synthesis of a wide range of products, including specialty chemicals, polymers, and additives.
Overall, 4-(4-METHYLPHENYL)-3-BUTEN-2-ONE 97 plays a vital role in both the pharmaceutical and chemical industries due to its ability to participate in the Reformatsky reaction and contribute to the synthesis of essential compounds and materials.

InChI:InChI=1/C11H12O/c1-9-3-6-11(7-4-9)8-5-10(2)12/h3-8H,1-2H3/b8-5+

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 67-64-1 acetone 
• 141-97-9 ethyl acetoacetate 
• 127623-84-1 1-(4-Methylphenyl)-2-butyn-1-ol 
• 106-96-7 propargyl bromide 
• 78-94-4 methyl vinyl ketone 
• 624-31-7 4-tolyl iodide 
• 135689-01-9 4-hydroxy-4-(4-methylphenyl)-butan-2-one 
• 7774-79-0 4-(4-methylphenyl)butan-2-one 
• 67-63-0 isopropyl alcohol 
• 1261958-97-7 1-(3-benzyloxybut-1-enyl)-4-methylbenzene 
• 589-18-4 4-Methylbenzyl alcohol 
• 122-00-9 para-methylacetophenone 
• 1439-36-7 1-triphenylphosphoranylidene-2-propanone 

Downstream Products

• 7774-79-0 4-(4-methylphenyl)butan-2-one 
• 89538-71-6 1-methyl-3-p-tolyl-propylamine 
• 77651-25-3 3,4-dibromo-4-p-tolyl-butan-2-one 
• 39777-55-4 bis(4-methylstyryl)ketone 
• 93298-17-0 4,4-di-p-tolylbutan-2-one 
• 130028-17-0 (E)-4-p-Tolyl-but-3-enoic acid methyl ester 
• 143111-92-6 (E)-5-Diethylamino-1-p-tolyl-pent-1-en-3-one; hydrobromide 
• 143111-90-4 (E)-5-Dimethylamino-1-p-tolyl-pent-1-en-3-one; hydrobromide 
• 97481-57-7 6-Amino-1,3-dimethyl-5-[(E)-1-methyl-3-p-tolyl-prop-2-en-(Z)-ylideneamino]-1H-pyrimidine-2,4-dione 
• 93626-90-5 1,3-dimethyl-5-p-tolyl-2-aza-1-oxapentadiene 
• 61888-37-7 5-(4-methylphenyl)-1,3-cyclohexanedione 
• 54064-35-6 1-(2-(p-tolyl)cyclopropyl)ethanone 

Relevant academic research and scientific papers

Enantioselective one-pot two-step synthesis of hydrophobic allylic alcohols in aqueous medium through the combination of a Wittig reaction and an enzymatic ketone reduction

A one-pot two-step process for the enantioselective synthesis of hydrophobic allylic alcohols was developed, which comprises ketone formation by the Wittig reaction and their enzymatic in situ biotransformation into the desired target products. By means of this combined Wittig reaction and bioreduction, the allylic alcohols were prepared with conversions of up to 90 %, and with excellent enantioselectivities of >99 % ee. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.

Green sustainable approach for carbon–carbon bond-forming reactions using FeNPs/DETA@rGO nano-catalyst

We have fabricated eccentric highly persuasive bifunctional FeNPs/DETA@rGO (where DETA = diethylenetriamine) nano-catalyst with a dual activation mechanism by presenting aliphatic amine on the basal and/or edges sites offering a base characteristic and Fe

An efficient Pd@Pro-GO heterogeneous catalyst for the α, β-dehydrogenation of saturated aldehyde and ketones

An Efficient Pd@Pro-GO heterogeneous catalyst was developed that can promote the α, β-dehydrogenation of saturated aldehyde and ketones in the yield of 73% ? 92% at mild conditions without extra oxidants and additives. Pd@Pro-GO heterogeneous catalyst was synthesized via two steps: firstly, the Pro-GO was obtained by the esterification reaction between graphene oxide (GO) and N-(tert-Butoxycarbonyl)-L-proline (Boc-Pro-OH), followed by removing the protection group tert-Butoxycarbonyl (Boc), which endowed the proline-functionalized GO with both the lewis acid site (COOH) and the bronsted base site (NH), besides, the pyrrolidine of proline also can form imine with aldehydes to activate these substrates; Second, palladium was dispersed on the proline-functionalized GO (Pro-GO) to obtained heterogeneous catalyst Pd@Pro-GO. Mechanistic studies have shown that the Pd@Pro-GO-catalyzed α,β-dehydrogenation of saturated aldehyde and ketones was realized by an improved heterogeneously catalyzed Saegusa oxidation reaction. Based on the obove characteristics, the Pd@Pro-GO will be widely used in the transition metal catalytic field.

PQQ-dependent Dehydrogenase Enables One-pot Bi-enzymatic Enantio-convergent Biocatalytic Amination of Racemic sec-Allylic Alcohols

The asymmetric amination of secondary racemic allylic alcohols bears several challenges like the reactivity of the bi-functional substrate/product as well as of the α,β-unsaturated ketone intermediate in an oxidation-reductive amination sequence. Heading for a biocatalytic amination cascade with a minimal number of enzymes, an oxidation step was implemented relying on a single PQQ-dependent dehydrogenase with low enantioselectivity. This enzyme allowed the oxidation of both enantiomers at the expense of iron(III) as oxidant. The stereoselective amination of the α,β-unsaturated ketone intermediate was achieved with transaminases using 1-phenylethylamine as formal reducing agent as well as nitrogen source. Choosing an appropriate transaminase, either the (R)- or (S)-enantiomer was obtained in optically pure form (>98 % ee). The enantio-convergent amination of the racemic allylic alcohols to one single allylic amine enantiomer was achieved in one pot in a sequential cascade.

Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein

The autophagic ubiquitin-like protein LC3 functions through interactions with LC3-interaction regions (LIRs) of other autophagy proteins, including autophagy receptors, which stands out as a promising protein–protein interaction (PPI) target for the intervention of autophagy. Post-translational modifications like acetylation of Lys49 on the LIR-interacting surface could disrupt the interaction, offering an opportunity to design covalent small molecules interfering with the interface. Through screening covalent compounds, we discovered a small molecule modulator of LC3A/B that covalently modifies LC3A/B protein at Lys49. Activity-based protein profiling (ABPP) based evaluations reveal that a derivative molecule DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells. DC-LC3in-D5 compromises LC3B lipidation in vitro and in HeLa cells, leading to deficiency in the formation of autophagic structures and autophagic substrate degradation. DC-LC3in-D5 could serve as a powerful tool for autophagy research as well as for therapeutic interventions.

Cobalt-Catalyzed Asymmetric 1,4-Reduction of β,β-Dialkyl α,β-Unsaturated Esters with PMHS

A cobalt-catalyzed asymmetric reduction of β,β-dialkyl α,β-unsaturated esters with polymethylhydrosiloxane (PMHS) was reported to deliver the corresponding esters containing a chiral trialkyl carbon center at β-position with up to 97 % yield and 98 % ee. The chiral tridentate ligand oxazoline iminopyridine (OIP) could perform well for the asymmetric reduction instead of chiral bidentate ligands. This operationally simple protocol shows a broad scope of substrates using one equivalent of readily available PMHS as a cheap and easy-to-handle reductive reagent.

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

Organocatalytic diastereo- And enantioselective oxa-hetero-Diels-Alder reactions of enones with aryl trifluoromethyl ketones for the synthesis of trifluoromethyl-substituted tetrahydropyrans

Tetrahydropyran derivatives are found in bioactives, and introduction of the trifluoromethyl group into molecules often improves biofunctions. Here we report diastereo- and enantioselective oxa-hetero-Diels-Alder reactions catalyzed by amine-based catalyst systems that afford trifluoromethyl-substituted tetrahydropyranones. Catalyst systems and conditions suitable for the reactions to provide the desired diastereomer products with high enantioselectivities were identified, and various trifluoromethyl-substituted tetrahydropyranones were synthesized with high diastereo- and enantioselectivities. Mechanistic investigation suggested that the reactions involve a [4 + 2] cycloaddition pathway, in which the enamine of the enone acts as the diene and the ketone carbonyl group of the aryl trifluoromethyl ketone acts as the dienophile. In this study, tetrahydropyran derivatives with the desired stereochemistry that are difficult to synthesize by previously reported methods were concisely obtained, and the range of tetrahydropyran derivatives that can be synthesized was expanded. This journal is

Iron-Catalyzed ?±,?-Dehydrogenation of Carbonyl Compounds

An iron-catalyzed α,β-dehydrogenation of carbonyl compounds was developed. A broad spectrum of carbonyls or analogues, such as aldehyde, ketone, lactone, lactam, amine, and alcohol, could be converted to their α,β-unsaturated counterparts in a simple one-step reaction with high yields.

Piperlongumine derivative as well as preparation method and application thereof

The invention discloses a Piperlongumine derivative as well as a preparation method and application thereof. The Piperlongumine derivative has the following structure: the Piperlongumine derivative provided by the invention contains a plurality of Michael addition receptor units, and the novel structure improves the electrophilicity, so that the Piperlongumine derivative has good protein targetingpotential, and the Piperlongumine derivative has a good inhibition effect on thioredoxin reductase; in an antitumor bioactive in-vitro screening experiment, the derivative also has a certain inhibition effect on the growth of tumor cells, and meanwhile, the derivative has an effect of promoting the generation of active oxygen in A549 human lung cancer cells.